All In Biotech

Drug Trial Radar · NCT07586514

A Study to Assess Safety, Tolerability and Exposure of 4ET1103 in Healthy Human Volunteers

A First in Human Randomized, Double-Blind, Placebo Controlled Single Ascending Dose (SAD) Phase 1 Study to Determine Safety, Tolerability, and Pharmacokinetics of 4ET1103 in Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Apr 18, 2025

Primary completion

Aug 18, 2025

Study completion Aug 18, 2025

Sponsor

Lead sponsor
4E TherapeuticsIndustry
Sponsor type
Industry
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
First posted
May 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will dose healthy human volunteers with either active drug (4ET1103) or placebo. Each study subject will receive a single dose of either active drug or placebo, and will then be monitored for safety, tolerability and exposure of active drug.

Conditions

  • Neuropathic Pain

Interventions

  • LY4286533Drug

    MNK inhibitor for treatment of neuropathic pain

  • placeboDrug

    Placebo for MNK inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in hematology parametersTime frame: 14 days
  2. Change from baseline in serum chemistry parametersTime frame: 14 days
  3. Change from baseline in urinalysis parameters.Time frame: 14 days
  4. Change from baseline in coagulation parametersTime frame: 14 days
  5. Change from bassline in vital signsTime frame: 14 days
  6. Change from baseline in 12-lead ECG parametersTime frame: 14 days
  7. Incidence of treatment-emergent adverse events (TEAEs)Time frame: 72 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • PPD

    Austin, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.